Approving AI Tools Faster in Automotive Without Losing Control
- Automotive & Manufacturing
Publishing 3 December 2026
Research brief · HLS-13
How fast can we approve new AI tools? We map how healthcare and life sciences decision units approach this choice: who decides, who can veto, what AI leaders are doing differently, and what it means for the technology partners they buy from.
In healthcare and life sciences, the decision to approve new AI tools is led by the CISO, but the chief risk and compliance officer and the legal and privacy team can stop it. In healthcare and life sciences, any tool that may touch patient or research data faces privacy and validation reviews. A typical large healthcare and life sciences organisation involves around 11.1 executives in AI decisions.
Full report: 8 to 10 pages, PDF.
How we label evidence is explained in our methodology.
This brief is planned for 3 December 2026. Request early access and we'll send it to you as soon as it is ready.
Publishing 3 December 2026
Publishing 3 December 2026
Publishing 3 December 2026
Publishing 7 January 2027
Publishing 3 December 2026
One considered briefing a month on how organisations decide on, buy and adopt AI. Unsubscribe at any time.